Surgery Partners (SGRY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Oct, 2026Executive summary
Signed a definitive agreement for HealthSpan Partners, an affiliate of Bon Secours Mercy Health, to acquire the business in an all-cash transaction valued at $5.7B enterprise value; the entity would become privately held.
Transaction expected to close in Q1 2027, subject to shareholder and regulatory approvals and customary closing conditions; operations remain independent until closing.
After closing, operations, name, brand and Brentwood, TN headquarters are expected to remain; day-to-day payor contacts will not change.
Existing payor contracts remain in effect under agreed terms, with ongoing facility negotiations and notices to payors as required by contract.
Voting matters and shareholder proposals
Shareholder approval is a condition to closing; a definitive proxy statement and joint Schedule 13E-3 are planned, and shareholders are urged to review them before voting.
Directors, executive officers and employees may be deemed solicitation participants; their direct and indirect interests will be described in transaction filings.
Risk oversight and compliance
Closing risks include unsatisfied conditions, regulatory delays, lack of shareholder approval, potential termination or litigation, and disruption to business relationships; completion is not assured.
Other identified risks include transaction costs, management distraction, retaining key personnel and business uncertainty during the transaction period.
Restrictions during the transaction period may limit pursuit of certain business opportunities or strategic transactions.
Latest events from Surgery Partners
- Amended HealthSpan deal raises value to up to ~$6.0B with capped per-share delay payments.SGRY
Proxy filing - Board backs HealthSpan’s amended ~$6.0B all-cash deal, targeting a Q1 2027 close.SGRY
Proxy filing - Same-facility growth partly offset Idaho divestiture drag; merger amended to $25 per share.SGRY
Q3 2026 - Revised merger offers $25 per share plus up to $1.61 in delay payments.SGRY
Proxy filing - HealthSpan Partners deal targets a Q1 2027 close, pending approvals and a shareholder vote.SGRY
Proxy filing - HealthSpan Partners’ ~$5.7B cash acquisition awaits shareholder and regulatory approval.SGRY
Proxy filing - A $23.50-per-share acquisition combines cash consideration with Bain Capital’s equity rollover.SGRY
Proxy filing - Q2 2026 revenue rose 2.7%, guidance reaffirmed, and Idaho Falls divestiture to generate $795M.SGRY
Q2 2026 - Q3 revenue rose 14.3% and Adjusted EBITDA 21.9%, led by high acuity cases and acquisitions.SGRY
Q3 2024